NasdaqGS:SRPTBiotechs
Sarepta Therapeutics (SRPT) Brings In New CEO Severino Is Its R&D Strategy Entering a New Phase?
Sarepta Therapeutics has appointed Michael Severino, M.D., a veteran of AbbVie, Amgen, Merck and most recently Tessera Therapeutics, as its Chief Executive Officer effective July 28, 2026, succeeding Douglas Ingram.
By combining the CEO role with a seat on Sarepta’s board, Severino’s broad R&D and corporate strategy background could shape how the company prioritizes its gene therapy and RNA-based rare disease programs.
Next, we’ll explore how bringing former AbbVie president Michael Severino...